November 22, 2018
Mundipharma has concluded an exclusive development and marketing agreement in Japan for Invossa, a cell therapy treatment for osteoarthritis of the knee developed by the South Korean biopharmaceutical company Kolon Life Science. Invossa is a gene therapy that uses allogeneic...read more